Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KETA-BID: S-ketamine for cortical spreading depolarisation in severe acute brain injury
2024-515315-22-00Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH) and traumatic brain injury (TBI) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Occurrence of cortical spreading depolarisations. Planned start Sep 2024; status: authorised.
02
Drugs
esketamine
03
Conditions
subarachnoid hemorrhage (SAH)intracerebral hemorrhage (ICH)traumatic brain injury (TBI)
Beyond the preview
Go deeper on 2024-515315-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515315-22-00.